13549-1-AP

antibody from Proteintech Group

Targeting: NAPRT NAPRT1, PP3856

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Antibody Data

Product number

13549-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#13549-1-AP, RRID:AB_2151014

Product name

NAPRT1 antibody

Antibody type

Polyclonal

Description

NAPRT1 antibody (Cat. #13549-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IP, WB,ELISA.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

NAD(+) supplementation improves mitochondrial functions and normalizes glaucomatous trabecular meshwork features.

Liu Y, Bu Q, Hu D, Chen C, Zhu J, Zhou Q, Li Z, Pan X
Experimental cell research 2024 Jul 1;440(1):114137

---

Epigenetic drug library screening reveals targeting DOT1L abrogates NAD(+) synthesis by reprogramming H3K79 methylation in uveal melanoma.

Gu X, Hua Y, Yu J, Yang L, Ge S, Jia R, Chai P, Zhuang A, Fan X
Journal of pharmaceutical analysis 2023 Jan;13(1):24-38

---

Jian-Pi-Yi-Shen formula alleviates renal fibrosis by restoring NAD+ biosynthesis in vivo and in vitro.

Gao L, Huang X, Deng R, Wu S, Peng Y, Xiong G, Lu J, Liu X
Aging 2023 Dec 28;16(1):106-128

---

NAD(+) Anabolism Disturbance Causes Glomerular Mesangial Cell Injury in Diabetic Nephropathy.

Li X, Li Y, Li F, Chen Q, Zhao Z, Liu X, Zhang N, Li H
International journal of molecular sciences 2022 Mar 22;23(7)

---

Glucose-6-phosphate dehydrogenase exerts antistress effects independently of its enzymatic activity.

Jin X, Li X, Li L, Zhong B, Hong Y, Niu J, Li B
The Journal of biological chemistry 2022 Dec;298(12):102587

---

Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease.

Liu X, Luo D, Huang S, Liu S, Zhang B, Wang F, Lu J, Chen J, Li S
Frontiers in physiology 2021;12:723690

---

Hyperglycemia-reduced NAD(+) biosynthesis impairs corneal epithelial wound healing in diabetic mice.

Li Y, Li J, Zhao C, Yang L, Qi X, Wang X, Zhou Q, Shi W
Metabolism: clinical and experimental 2021 Jan;114:154402

---

NAD(+) Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.

Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, Cui X, He Y, Xiang W, Han Q, Tang L, Yang W, Wang H
Cell metabolism 2021 Jan 5;33(1):110-127.e5

---

NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.

Li XQ, Lei J, Mao LH, Wang QL, Xu F, Ran T, Zhou ZH, He S
Frontiers in oncology 2019;9:736

---

CD38 is methylated in prostate cancer and regulates extracellular NAD().

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS
Cancer & metabolism 2018;6:13

---

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH
Kidney international 2017 Oct;92(4):922-933

---

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH
Molecular cancer therapeutics 2016 Sep;15(9):2119-29

---

Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT, Chini EN
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Jan 1;20(1):120-30

---

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.

Cerna D, Li H, Flaherty S, Takebe N, Coleman CN, Yoo SS
The Journal of biological chemistry 2012 Jun 22;287(26):22408-17

---

Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.

Olesen UH, Hastrup N, Sehested M
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2011 Apr;119(4-5):296-303

---

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D, Bernier C, Branchaud S, Chan H, Dairi K, Gilbert K, Goulet D, Gratton MO, Isakau H, Jang A, Khadir A, Koch E, Lavoie M, Lawless M, Nguyen M, Paquette D, Turcotte E, Berger A, Mitchell M, Shore GC, Beauparlant P
Molecular and cellular biology 2009 Nov;29(21):5872-88

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The NAPRT1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human NAPRT1. This antibody recognizes human,mouse,rat antigen. The NAPRT1 antibody has been validated for the following applications: ELISA, WB analysis.

Appendix

13549-1-AP.pdf

Show more

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

HepG2 cells were subjected to SDS PAGE followed by western blot with 13549-1-AP(NAPRT1 antibody) at dilution of 1:300

Sample type

cell line

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

L02 cells were subjected to SDS PAGE followed by western blot with 13549-1-AP(NAPRT1 antibody) at dilution of 1:300

Sample type

cell line